Welcome to our dedicated page for Barclays SEC filings (Ticker: BCS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Barclays PLC (BCS) SEC filings page provides access to the company’s regulatory disclosures as a foreign private issuer, including Form 6-K current reports and Form 25 notices for specific securities. Barclays uses these filings to furnish information it provides to the London Stock Exchange and other markets, giving US investors a structured view of its capital, share structure, regulatory interactions and securities actions.
For a commercial and investment bank like Barclays, Form 6-K reports are central. They include quarterly and other results announcements, details of share buy-back programmes and total voting rights, Bank of England stress test outcomes, notices of redemption for capital instruments, and Director/PDMR Shareholding disclosures. These documents show how Barclays manages its common equity Tier 1, Tier 1 capital, total capital and leverage ratios, and how it adjusts its share capital through repurchases and cancellations.
Barclays’ filings also cover structured products and debt securities. Business Wire announcements and related SEC materials describe cash tender offers and consent solicitations for iPath-branded exchange-traded notes, as well as issuer redemptions of ETN series. Selected risk considerations in these documents explain principal risk, market and volatility risk, credit risk of Barclays Bank PLC, concentration risk, liquidity considerations and tax uncertainty for ETN holders.
In addition, Form 25 (25-NSE) notifications document the removal from listing and/or registration on the New York Stock Exchange of particular Barclays debt issues, such as fixed rate senior notes maturing in 2026. These filings relate to specific note classes rather than the Barclays ADRs themselves.
On Stock Titan, these filings are updated as they appear on EDGAR and can be paired with AI-powered summaries that highlight key points in lengthy documents. Users can quickly identify capital ratios, share count changes, insider transactions and the terms of redemptions or tenders without reading every page, while still having direct access to the full original filings for detailed review.
Barclays PLC reports extensive share activity in December 2025, mainly driven by its previously announced buy-back programme. On multiple trading days from late November through 30 December 2025, the bank bought ordinary shares on the London Stock Exchange from Citigroup Global Markets Limited and intends to cancel all of them. After the 28 November purchase and related cancellations, issued share capital consisted of 13,906,092,145 ordinary shares with voting rights, and after the 30 December purchase it will consist of 13,864,674,344 ordinary shares.
The company also discloses routine total voting rights information as of 30 November 2025, confirming 13,906,092,145 ordinary shares in issue and none held in treasury. Several senior executives and other persons discharging managerial responsibilities report transactions in Barclays shares and ADSs, including disposals via the nominee service, deliveries of shares under employee and remuneration plans, and sales to cover tax and social security liabilities. In addition, Barclays has applied to block list 20,000,000 new ordinary shares for issue under the Barclays Group Share Value Plan, which will rank equally with existing shares when admitted.
Barclays PLC reports the results of the Bank of England’s 2025 capital stress test, confirming that the bank remains sufficiently capitalised throughout the adverse scenario. The test shows a minimum stressed Common Equity Tier 1 (CET1) ratio of 8.8% before and 9.3% after strategic management actions, compared with a minimum requirement of 7.2%. Barclays’ actual CET1 ratio was 13.6% as of 31 December 2024 and 14.1% in Q3 2025, supporting its stated capital target range of 13–14%.
The Tier 1 leverage ratio fell to a minimum stressed level of 4.0% before and 4.2% after management actions, versus a minimum requirement of 3.25%, compared with actual levels of 5.0% at year-end 2024 and 4.9% in Q3 2025. Total capital and Tier 1 capital ratios also remained above stressed low points and requirements, underscoring Barclays’ description of its balance sheet as robust and resilient.
Barclays PLC reports a series of November 2025 share repurchases and related share capital updates. On multiple trading days between 31 October and 27 November 2025, the bank bought back and intends to cancel blocks of ordinary shares of 25 pence each on the London Stock Exchange, with daily volumes typically between about 2 million and 4 million shares and prices generally in the 390p–430p range.
As of 31 October 2025, Barclays’ issued share capital consisted of 13,922,759,891 ordinary shares with voting rights, falling to 13,907,858,099 after the 27 November 2025 cancellation. Since the commencement of the buy-back programme announced on 30 July 2025, the bank reports that by 25 November 2025 it had purchased 261,554,089 ordinary shares on the London Stock Exchange at a volume weighted average price of 381.4737p per share. The filing also discloses routine management share dealings under employee and nominee arrangements.
Barclays PLC has completed its HY 2025 share buy-back and is starting a new programme. On 26 November 2025 it bought 539,869 ordinary shares at a volume weighted average price of 414.9236p for cancellation. After cancelling these and prior repurchases, the issued share capital will be 13,909,748,427 ordinary shares with voting rights.
Since the HY 2025 buy-back began, Barclays has repurchased 262,093,958 ordinary shares at a volume weighted average price of 381.5426p, for total consideration of approximately £1 billion. The company will now commence its Q3 2025 buy-back, previously announced on 23 October 2025, to purchase ordinary shares for up to £500m, with a maximum of 1,174,692,434 shares eligible for repurchase.
Barclays PLC (BCS) filed a Form 13F holdings report listing institutional equity positions. The filing reports 11,877 information table entries with an aggregate value of $461,228,194,391. The report includes 6 other managers. It was signed by Suejean Mott, Director, in Whippany, NJ on 11-12-2025.
Other included managers named in the filing include Barclays Bank PLC, Barclays Capital Inc., Barclays Capital Securities Ltd, Barclays Bank (Suisse) SA, Barclays Capital Luxembourg SaRL, and Barclays Investment Solutions Ltd.
Barclays PLC announced the full redemption of its $1,500,000,000 6.125% Fixed Rate Resetting Perpetual Subordinated Contingent Convertible Securities, with redemption set for December 15, 2025.
The notes will be redeemed at 100% of principal plus accrued and unpaid interest from, and including, September 15, 2025 to, but excluding, the redemption date. On that date, the redemption price becomes due and interest will cease to accrue. Prior to redemption, Barclays will irrevocably deposit funds sufficient to pay the total redemption price with the trustee or a paying agent.
The listing of these securities on the London Stock Exchange’s International Securities Market will be canceled on, or shortly after, December 15, 2025. Holders may surrender securities and receive payment via The Bank of New York Mellon, 160 Queen Victoria Street, London EC4V 4LA.
Barclays PLC filed a Form 6-K detailing October updates to its ongoing share buy-back announced on 30 July 2025. The company reported multiple daily repurchases on the London Stock Exchange, each intended for cancellation. As of the purchase dated 30 October 2025, cumulative repurchases since programme commencement reached 205,529,348 ordinary shares at a volume‑weighted average price of 374.4285p per share.
Following each cancellation, Barclays disclosed the updated share count; after the 30 October purchases, issued share capital stood at 13,926,591,777 ordinary shares with voting rights. The filing also notes a block listing application for 68,000,000 shares for employee share schemes, with admission expected to be effective on 16 October 2025, and routine disclosures of director/PDMR share transactions. Barclays states there are no ordinary shares held in Treasury.
Barclays PLC (BCS): NYSE filed Form 25 to remove a debt security from listing and/or registration. The action covers Barclays’ 7.325% Fixed Rate Resetting Senior Callable Notes due 2026 on the New York Stock Exchange. The filing states the Exchange has complied with its rules under 17 CFR 240.12d2-2(b), and notes issuer compliance under 17 CFR 240.12d2-2(c) for voluntary withdrawal procedures.
Barclays PLC will commence a share buy-back of Ordinary Shares for up to £500m. It will start on the business day after completion of the £1,000m buy-back launched on 30 July 2025 and end no later than 20 April 2026, subject to regulatory approval remaining in place.
The purpose is to reduce share capital; purchased shares will be cancelled. Citigroup Global Markets Limited will conduct on‑market purchases as riskless principal under pre‑set parameters and applicable UK rules, limited to the London Stock Exchange. No repurchases will be made in the United States or in respect of ADRs.
The maximum number of shares is capped by the 2025 Authority of 1,436,786,392 Ordinary Shares, less those purchased (and to be purchased) under the £1,000m programme.
Barclays PLC reported Q3 2025 results with Group RoTE of 10.6%, total income of £7.2bn (up 9% year-on-year) and profit before tax of £2.1bn. The board announced a £500m share buyback and upgraded 2025 RoTE guidance to greater than 11%, reaffirming a 2026 target of greater than 12%.
Capital and balance sheet remained strong, with a CET1 ratio of 14.1% and TNAV per share of 392p; including the buyback, CET1 as of 30 September 2025 would be 13.9%. Year-to-date, RoTE was 12.3% and EPS reached 35.1p. Loan loss rate was 57bps in Q3, reflecting £0.6bn of credit impairment charges, including a c.£110m single-name charge in the Investment Bank and a £65m day-1 impact from the GM portfolio acquisition. Operating expenses rose to £4.5bn, including a £235m charge for motor finance redress. All divisions delivered double-digit RoTE in the quarter, and Group NII (ex‑IB and Head Office) was £3.3bn, up 16% year-on-year.